ctDNA Reveals Genomic Differences of mRCC During First-, Second-Line Therapy

Video
Conference|ASCO Gastrointestinal Cancer Symposium

This video examines a new study that looked at genomic alterations in the circulating tumor DNA of patients with metastatic RCC during first- and second-line therapies.

In this video, Sumanta K. Pal, MD, of City of Hope in Duarte, California, discusses a study that looked at differences in genomic alterations in the circulating tumor DNA (ctDNA) of patients with metastatic renal cell carcinoma (mRCC) in the first- and second-line treatment setting.

The researchers assessed ctDNA in 224 mRCC patients and found that among those with detected genomic alterations on second-line (56 patients) and first-line (64 patients) therapy, there were differences in TP53 (49% vs 25%, respectively), PIK3CA (17% vs 8%), NF1 (20% vs 15%), and others. Compared with patients still on first-line therapy, differences were even more stark among second-line patients who had previously received anti-VEGF therapy: TP53 (64% vs 31%), PIK3CA (29% vs 8%), and NF1 (29% vs 4%), possibly pointing to mechanisms and pathways of resistance.

The study (abstract 434) was presented at the 2017 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium, held February 16–18 in Orlando, Florida.

Recent Videos
An expert from the University of California, Los Angeles suggests that the NALIRIFOX may be a beneficial treatment for patients with pancreatic ductal adenocarcinoma.
Patients with metastatic pancreatic ductal adenocarcinoma who receive NALIRIFOX tend to have more gastrointestinal toxicity while nab-paclitaxel/gemcitabine results in more cytopenias, according to an expert from University of California, Los Angeles.
An expert from the University of California, Los Angeles described the purpose and design of the phase 3 NAPOLI-3 study, assessing NALIRIFOX in metastatic pancreatic ductal adenocarcinoma.
An expert from the Mayo Clinic discusses how findings from the ongoing phase 3 MOUNTAINEER trial may enable access to tucatinib, trastuzumab, and chemotherapy in earlier lines of treatment for patients with HER2-positive metastatic colorectal cancer.
Zev A. Wainberg, MD, discusses future research efforts for the treatment of patients with advanced gastric cancer.
Ghassan K. Abou-Alfa, MD, detailed the evolution of treatment options for unresectable hepatocellular carcinoma prior to the phase 3 HIMALAYA study and the reasons for launching the trial.
Zev A. Wainberg, MD, spoke to the rationale for examining the efficacy of pembrolizumab alone and in combination with chemotherapy for patients with advanced gastric and gastroesophageal junction adenocarcinoma.
In an interview with CancerNetwork® during the 2022 American Society of Clinical Oncology Gastrointestinal Cancer Symposium, Zev A. Wainberg, MD, discussed key updates from the phase 3 KEYNOTE-062 trial, examining pembrolizumab plus or minus chemotherapy for patients with advanced gastric and gastroesophageal junction adenocarcinoma.
Kelley Lauren Coffman, MD
Kelley Lauren Coffman, MD
Related Content
Results from the randomized LASRE trial support the use of laparoscopic-assisted surgery for patients with low rectal cancer.

Laparoscopic Surgery Shows Noninferior DFS Vs Open Surgery in Rectal Cancer

Russ Conroy
January 29th 2024
Article

Results from the randomized LASRE trial support the use of laparoscopic-assisted surgery for patients with low rectal cancer.

Jun Gong, MD, and Daneng Li, MD, spoke about trials they feel can impact the gastrointestinal space during a CancerNetwork® X Space.

Expert Perspectives on 2024 ASCO GI Cancers Symposium Trial Updates

Jun Gong, MD;Daneng Li, MD
February 19th 2024
Podcast

Jun Gong, MD, and Daneng Li, MD, spoke about trials they feel can impact the gastrointestinal space during a CancerNetwork® X Space.

Adjuvant chemotherapy does not yield an improvement in ctDNA clearance compared with observation among patients with stage II colon cancer in the phase 2/3 COBRA trial.

ctDNA Does Not Confer Chemo Efficacy in Stage II CRC Following Surgery

Tony Berberabe, MPH
January 23rd 2024
Article

Adjuvant chemotherapy does not yield an improvement in ctDNA clearance compared with observation among patients with stage II colon cancer in the phase 2/3 COBRA trial.

Active Surveillance in Small Renal Masses

Active Surveillance in Small Renal Masses

Phillip M. Pierorazio, MD;Ridwan Alam
February 20th 2017
Podcast

In this interview we discuss a new study that looked at the outcomes of patients with small renal masses who were followed with active surveillance.

Neoadjuvant botensilimab plus balstilimab appears to be safe and effective in patients with colorectal cancer regardless of mismatch repair status in the phase 2 NEST-1 trial.

Botensilimab Combo Elicits Sustained Responses in Colorectal Cancer

Ashling Wahner
January 21st 2024
Article

Neoadjuvant botensilimab plus balstilimab appears to be safe and effective in patients with colorectal cancer regardless of mismatch repair status in the phase 2 NEST-1 trial.

Real-world data suggest a role for noncytotoxic chemotherapy treatments such as EGFR inhibitors beyond the frontline setting for patients with metastatic colorectal cancer.

Data Show Increased Bevacizumab/FOLFOXIRI Use in Younger mCRC Population

Darlene Dobkowski, MA
January 21st 2024
Article

Real-world data suggest a role for noncytotoxic chemotherapy treatments such as EGFR inhibitors beyond the frontline setting for patients with metastatic colorectal cancer.